ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: FLARE

Tigulixostat Appears Promising for the Treatment of Gout

Michele B. Kaufman, PharmD, BCGP  |  February 2, 2022

In a phase 2 study, tigulixostat treatment proved safe for lowering serum uric acid (sUA) levels in patients with gout.

Filed under:ACR ConvergenceConditionsDrug UpdatesGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence – GoutACR Convergence 2021ACR Convergence 2021 – GoutGoutserum uric acidtigulixostat

FDA Approves Secukinumab for Children with Enthesitis-Related Arthritis & PsA

Michele B. Kaufman, PharmD, BCGP  |  February 2, 2022

The FDA has approved the use of secukinumab for pediatric patients with enthesitis-related arthritis and psoriatic arthritis, after research showed a longer time to disease flare than placebo.

Filed under:ConditionsDrug UpdatesPediatric Conditions Tagged with:enthesitis-related arthritis (ERA)FDAFDA approvalPediatricPediatric RheumatologyPsApsoriatic arthritissecukinumabU.S. Food and Drug Administration (FDA)

Prokopenko Oleg / shutterstock.com

Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout

Vanessa Caceres  |  January 10, 2022

A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (metho­trexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study…

Filed under:ConditionsDrug UpdatesGout and Crystalline ArthritisResearch Rheum Tagged with:GoutGout Resource CenterMethotrexatepegloticase

COVID-19 Vaccination in Patients with Rheumatic Disease

Arthritis & Rheumatology  |  January 5, 2022

In January A&R, Simon et al. report a study to assess humoral and cellular immune responses after infection with, or vaccination against, SARS-CoV-2 in patients with B cell depletion and controls who are B cell competent, finding that B cell depletion completely blocks humoral but not T cell SARS-CoV-2 vaccination response. In the same issue, Connolly et al. evaluated disease flare and post-vaccination reactions in patients with rheumatic and musculoskeletal diseases following messenger RNA (mRNA) vaccination.

Filed under:ConditionsResearch Rheum Tagged with:Arthritis & RheumatologyCOVID-19flaremusculoskeletal diseaseResearchRheumatic DiseaseSARS-CoV-2vaccination

A positron emission tomography (PET) scan shows a 3 cm, hypermetabolic mass adjacent to the stomach.

Case Report: Elevated Inflammatory Markers & a Hypermetabolic Mass

Lisa L. Korn, MD, PhD, Mina L. Xu, MD, & Cristina Brunet, MD  |  December 16, 2021

Consulting rheumatologists often assess patients with atypical clinical presentations for the possibility of an underlying rheumatic disease. Inflammatory syndromes that are not clearly rheumatic in nature can be particularly challenging to diagnose. Here, we share the case of a young woman with a long-standing undiagnosed illness and highly elevated inflammatory markers, and describe the evaluation…

Filed under:Conditions Tagged with:Castleman's diseasemultidisciplinary care

Vax Hesitancy? Myths & Facts for Patients

Susan Bernstein  |  December 16, 2021

Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S. counties—particularly in the Southeast…

Filed under:Patient Perspective Tagged with:COVID-19vaccinationvaccine hesitancy

Alpha Tauri 3D Graphics / shutterstock.com

Rheumatic Complications from Immune Checkpoint Inhibitors

Nilasha Ghosh, MD, MS, & Anne R. Bass, MD  |  December 16, 2021

Immune checkpoint inhibitors (ICIs), such as anti-programmed cell-death 1/programmed death-ligand 1 (anti-PD-1/PD-L1) or anti-CTL-associated protein (anti-CTLA-4), have dramatically changed the treatment of advanced cancers over the past decade. ICIs block T cell inhibition, thus increasing the anti-tumor immune response. ICIs are used not only for metastatic cancer, but also as adjuvant treatment for some stage…

Filed under:Conditions Tagged with:immune checkpoint inhibitor (ICI)immune-related adverse events

Therapeutics for COVID-19: An update from ACR Convergence 2021

Lara C. Pullen, PhD  |  December 10, 2021

ACR CONVERGENCE 2021—Rheumatology patients who test positive for COVID-19 would benefit from early use of monoclonal antibodies, said Luis Ostrosky-Zeichner, MD, chief of the Division of Infectious Diseases, McGovern Medical School, University of Texas Health Science Center (UTHealth), Houston, in a session about effective treatment options for COVID-19. Acknowledging that the SARS-CoV-2 virus has already…

Filed under:ACR ConvergenceBiologics/DMARDsMeeting Reports Tagged with:ACR Convergence 2021COVID-19

Research on SLE, pJIA & More Highlighted in 2nd ACR Convergence 2021 Plenary Session

Samantha C. Shapiro, MD  |  December 9, 2021

Experts shined a spotlight on select abstracts of the latest rheumatology research, addressing such topics as racial disparities in the management of children with SLE, vitamin D or fish oil supplementation to prevent autoimmune disease & more.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLECOVID-19MIS-CPediatricpJIApolyarticular juvenile idiopathic arthritis

Pediatric Rheumatology Year in Review, 2021: Basic Science

Elizabeth Sloan, MD  |  December 9, 2021

ACR Convergence 2021—The field of pediatric rheumatology has benefited from significant developments in the basic and translational sciences over the past year, and it can be challenging to keep up with the latest discoveries. In the Basic Science section of the Pediatric Rheumatology Year in Review at ACR Convergence, Tiphanie Vogel, MD, PhD, assistant professor…

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLECOVID-19DADA2Pediatric

  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 72
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences